DP-1904, a specific inhibitor of thromboxane A2 synthesizing enzyme, suppresses ICAM-1 expression by stimulated vascular endothelial cells.
Intercellular adhesion molecule-1 (ICAM-1) is an antigen that is strongly expressed by vascular endothelial cells at sites of local inflammation and participates in the development of inflammation. In the present study, vascular endothelial cells were stimulated by inflammatory cytokines that promote thromboxane A2 synthesis to observe their effects on the expression and shedding of ICAM-1 on the cell surface. In addition, the suppressive effects of DP-1904 ([+/-]-6-[1-imidazolylmethyl]-5,6,7,8-tetrahydronaphthalene-2- carboxylic acid hydrochloride hemihydrate), a thromboxane A2 synthesis inhibitor, on ICAM-1 expression were evaluated. ICAM-1 expression on the surface of human umbilical vein endothelial cells was increased significantly by stimulation with interleukin-1 beta, tumor necrosis factor alpha (TNF alpha), thrombin and platelet-activating factor (PAF). DP-1904, an inhibitor of thromboxane A2 synthesis, significantly suppressed the expression of ICAM-1 on the surface of human vascular endothelial cells that had been stimulated by TNF alpha or PAF. These findings suggest that an enhanced expression of thromboxane A2 on human vascular endothelial cells is closely related to the expression of ICAM-1 on the surface of these cells.
Ishizuka
T
T
First Department of Internal Medicine, National Defense Medical College, Saitama, Japan.
Suzuki
K
K
Kawakami
M
M
Kawaguchi
Y
Y
Hidaka
T
T
Matsuki
Y
Y
Nakamura
H
H
D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D003513:Cycloheximide / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D011464:Epoprostenol / Q000096:biosynthesis; D016650:Fluorescein-5-isothiocyanate / Q000737:chemistry; D005455:Fluorescent Antibody Technique; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D018799:Intercellular Adhesion Molecule-1 / Q000096:biosynthesis* / Q000187:drug effects; D007375:Interleukin-1 / Q000494:pharmacology; D010972:Platelet Activating Factor / Q000494:pharmacology; D011450:Prostaglandin Endoperoxides, Synthetic / Q000494:pharmacology; D011994:Recombinant Proteins / Q000494:pharmacology; D013764:Tetrahydronaphthalenes / Q000494:pharmacology*; D013917:Thrombin / Q000494:pharmacology; D013928:Thromboxane A2 / Q000031:analogs & derivatives / Q000096:biosynthesis / Q000494:pharmacology; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D014471:Umbilical Veins / Q000187:drug effects / Q000378:metabolism
D007093:Imidazoles; D007375:Interleukin-1; D010972:Platelet Activating Factor; D011450:Prostaglandin Endoperoxides, Synthetic; D011994:Recombinant Proteins; D013764:Tetrahydronaphthalenes; D014409:Tumor Necrosis Factor-alpha; D018799:Intercellular Adhesion Molecule-1; D013928:Thromboxane A2; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D003513:Cycloheximide; C056295:nafagrel; D011464:Epoprostenol; D013917:Thrombin; D013930:Thromboxane-A Synthase; D016650:Fluorescein-5-isothiocyanate